The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $59.55

Today's change+2.07 +3.60%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.
 

Isis Pharmaceuticals Inc

Nasdaq: ISIS
Last

(U.S.) $59.55

Today's change+2.07 +3.60%
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Isis Pharmaceuticals Inc up sharply

Isis Pharmaceuticals Inc closed up sharply Thursday, rallying (U.S.)$2.07 or 3.60% to (U.S.)$59.55. Shares have lost 3.75% over the last five days, but have gained 49.47% over the last year to date. This security has outperformed the S&P 500 by 38.58% during the last year.

Key company metrics

  • Open(U.S.) $58.66
  • Previous close(U.S.) $57.48
  • High(U.S.) $60.04
  • Low(U.S.) $57.95
  • Bid / Ask-- / --
  • YTD % change+49.47%
  • Volume2,147,533
  • Average volume (10-day)3,479,214
  • Average volume (1-month)2,204,655
  • Average volume (3-month)2,356,449
  • 52-week range(U.S.) $22.25 to (U.S.) $65.13
  • Beta1.55
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.81
Updated December 18 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-54.98%

Isis Pharmaceuticals Inc has a net profit margin of -54.98%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.93%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue44572842
Total other revenue--------
Total revenue44572842
Gross profit-17-2-25-15
Total cost of revenue61595357
Total operating expense66645862
Selling / general / administrative4445
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)------0
Other operating expenses, total--------
Operating income-21-7-30-20
Interest income (expense), net non-operating-5-5-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-25-11-34-24
Income after tax-27-12-31-24
Income tax, total11-21
Net income-27-12-31-24
Total adjustments to net income--------
Net income before extra. items-27-12-31-24
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-27-12-31-24
Inc. avail. to common incl. extra. items-27-12-31-24
Diluted net income-27-12-31-24
Dilution adjustment----00
Diluted weighted average shares118118117116
Diluted EPS excluding extraordinary itemsvalue per share-0.23-0.10-0.27-0.21
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.23-0.10-0.27-0.21